SCHEMBL6782133

SCHEMBL6782133

O=C(C[N+](=O)[O-])c1ccc(F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.53
RAB9A P51151 2/20 0.53
PTPN1 P18031 1/20 0.53
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
HTR7 P34969 1/20 0.47
PLOD2 O00469 1/20 0.47
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
MAPT P10636 3/20 0.43
HTT P42858 2/20 0.43
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
POLB P06746 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
GSK3B P49841 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
KMT2A Q03164 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27858771 0.82 PTPN1 (0.52) NPC1RAB9APTPN1CA1CA2
SCHEMBL8478498 0.81 HDAC4 (0.45) NPC1RAB9APTPN1HTR7PLOD2
SCHEMBL105102 0.80 GSK3B (0.55) NPC1RAB9ACA1CA2CES2
SCHEMBL26687976 0.80 MAPK1 (0.57) NPC1RAB9AMAPTLMNAGSK3B
SCHEMBL26966709 0.80 KMT2A (0.44) NPC1CA1CA2CES1MAPT
SCHEMBL9386214 0.80 GSK3B (0.55) NPC1RAB9ACA1CA2CES2
SCHEMBL104262 0.80 GSK3B (0.53) NPC1RAB9ACES2CES1MAPT
SCHEMBL2867066 0.80 GSK3B (0.67) CA1CA2CES2CES1MAPT
SCHEMBL4658864 0.79 PTPN1 (0.58) PTPN1CES2CES1MAPTGSK3B
SCHEMBL9035708 0.79 CES2 (0.55) NPC1RAB9ACES2CES1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117924177-A Preparation method of pazopanib intermediate 2, 3-dimethyl-6-amino-2H-indazole and analogues thereof 南京杰运医药科技有限公司 2024-04-26 CN disclosed
CN-111704630-A 3-arylformyl naphtho-isoxazole or 3-arylformyl anthraceno-isoxazole derivative and synthetic method thereof 上海大学 2020-09-25 CN disclosed
CN-101985424-B Method for synthesizing o-nitroacetophenone compound UNIV ZHEJIANG TECHNOLOGY 2013-05-29 CN disclosed
CN-101985424-A Method for synthesizing o-nitroacetophenone compound UNIV ZHEJIANG TECHNOLOGY 2011-03-16 CN disclosed
US-6686505-B2 HYDROGENATION OF NITRO KETONE OR CYANO KETONE IN PRESENCE OF TRANSITION METAL COMPOUND CATALYST; AMINATION KANTO KAGUKU KABUSHIKI KAISHA (JP) 2004-02-03 US disclosed
US-20030171592-A1 Process for producing optically active amino alcohols and intermediates therefore KANTO KAGAKU KABUSHIKI KAISHA (JP) 2003-09-11 US disclosed
EP-1308435-A2 Process for producing optically active amino alcohols Kanto Kagaku Kabushiki Kaisha (JP) 2003-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171592-A1 Process for producing optically active amino alcohols and intermediates therefore ADH1A, NOS1, ADH5 NPC1 3259/4885RAB9A 2501/4885PTPN1 4827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.